Discover Camcevi.
  • ALREADY
    Set. Go!

Next-dose scheduler instructions

Our Next-Dose Scheduler lets you quickly calculate your patient’s next treatment date. Always refer to the full Prescribing Information for complete dosing and administration instructions.*

Reading LED Display

The LED screens are programmed with the current month/day and calculate 6 months from that date

The Current Dose LED display includes the current month (XX) and day (XX) that the dose is administered

To change the Current Dose date, push the “Set” button and use the up or down arrows to adjust the month and day

The Next Dose LED display automatically calculates 6 months out from the Current Dose date. The 6-month calculation, which varies from 182-184 days, factors in months ranging between 28-31 days and adjusts for leap years

SETTING THE DATE AND TIME

To set the Current Dose date, press “Set” and the month (M) display will flash. Using the up (▲) or down (▼) arrows, select the month and press “Set” again to save and advance to the Current Dose day (D) display. Use the up (▲) or down (▼) arrows to set the day, and press “Set” again to save and advance to the Next Dose display, where you will set the hour and minutes on a 24-hour clock

The Next Dose month (M) display should now be flashing. Using the up (▲) or down (▼) arrows, select the hour between 1 and 23 and press “Set” to save and advance to the Next Dose day (D) display to set the minutes. Again, use the (▲) or down (▼) arrows to adjust the minutes between 1 and 59 and press “Set” to save

Your Next-Dose Scheduler is now ready to accurately calculate the Next Dose date for your patients on CAMCEVI

*Recommended Dosage: 42 mg subcutaneously every 6 months.

    connect with a CAMCEVI® representative

    Complete the forms with your information to reach a CAMCEVI representative near you.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

    Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    CAMCEVI can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Interrupt CAMCEVI if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    Back to TopBack to Top button
    Back to TopBack to Top button